Zobrazeno 1 - 6
of 6
pro vyhledávání: ''
Autor:
Cathy Yi Xia, Anthony J. Gill, Michael E. Buckland, Stephen B. Fox, Amanda L. Hudson, Mark Li, Helen Westman, Bob T. Li, Stephen Clarke, Vivek Rathi, Michael Boyer, Viive M. Howell, Sarah A. Hayes, Heng Wei, Brandon Lau, Wendy A Cooper, Malinda Itchins, Michael Rodriguez, Nick Pavlakis
Publikováno v:
Oncologist
Since its discovery in 2007, we have seen the lives of patients diagnosed with advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancers (NSCLC) transform with the advent of molecular therapies with first-, second-, and third-g
Publikováno v:
The Oncologist. 24:e1141-e1147
Background The aim of this study was to explore outcomes of planned pregnancy in female patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitors (TKIs). Materials and Methods Data of female patients proceeding with a planned pregnan
Autor:
Xiuwen Wang, Jianhui Ma, Hong Luo, Jinwan Wang, Shukui Qin, Hanzhong Li, Ji-Yan Liu, Jun Li, Cheng Fu, Benkang Shi, Yuxian Bai, Ai Ping Zhou, Dingwei Ye, Xiu Bao Ren, Xianzhong Bai, Yan Song, Ying Cheng
Publikováno v:
The Oncologist. 24:e702-e708
Background Anlotinib is a tyrosine kinase inhibitor inhibiting angiogenesis. This multicenter, randomized phase II trial aimed to investigate the efficacy and safety of anlotinib in comparison with sunitinib as first-line treatment for patients with
Autor:
Andrew James Wiele, Lianchun Xiao, Amishi Yogesh Shah, Eric Jonasch, Tharakeswara K. Bathala, Pavlos Msaouel, Jeremy A. Ross, Nizar M. Tannir, Matthew T. Campbell, Andrew W. Hahn, Munevver Duran
Publikováno v:
Oncologist
Introduction Lenvatinib (Len) plus everolimus (Eve) is an approved therapy for metastatic renal cell carcinoma (mRCC) after first-line vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs), but limited data exist on the
Autor:
Todd M. Bauer, Alice T. Shaw, Gerson Peltz, Holger Thurm, Marc D. Chioda, Benjamin Solomon, Enriqueta Felip
Publikováno v:
The oncologist. 24(8)
Lorlatinib is a novel, highly potent, brain-penetrant, third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI), which has broad-spectrum potency against most known resistance mutations that can develop during treatment with crizotinib and second-ge
Autor:
Jeremy O. Jones, Josiah Hawks, David Gill, Gayatri Nachaegari, Robert A. Stephenson, Julia A. Batten, Christopher Dechet, Meghan Salgia, Christopher Martin, Roberto Nussenzveig, Sumanta K. Pal, William T. Lowrance, Ting Liu, Neeraj Agarwal, Benjamin L. Maughan, Kenneth M. Boucher
Publikováno v:
The Oncologist
Lessons Learned Pazopanib was not effective in altering the premetastatic niche in the neoadjuvant setting. Pazopanib was safe and well tolerated without any new safety signals. Background Vascular endothelial growth factor receptor 1 (VEGFR1) expres